Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
Niklas Schäfer(University Hospital Bonn), Ulrich Herrlinger(University of Tübingen), Dietmar Krex, Peter Vajkoczy(Humboldt-Universität zu Berlin), Stefan Grau(University of Cologne), Michael Ronellenfitsch(Goethe University Frankfurt), Roland Goldbrunner(University of Cologne), Christina Schaub(University of Bonn), Sied Kebir(University of Bonn), Astrid Weyerbrock(University of Freiburg), Claus Belka(LMU Klinikum), Oliver Schnell(Friedrich-Alexander-Universität Erlangen-Nürnberg), Peter Hau(University Hospital Regensburg), Veit Rohde(Universitätsmedizin Göttingen), Barbara Leutgeb(Goethe University Frankfurt), Oliver Grauer(University Hospital Münster), Theophilos Tzaridis(Sanford Burnham Prebys Medical Discovery Institute), Uwe Schlegel(Defence Research and Development Organisation), Mathias Hänel(Klinikum Chemnitz), Walter Stummer(University of Münster), Joachim P. Steinbach(Goethe University Frankfurt), Florian Ringel(Johannes Gutenberg University Mainz), Michael Sabel(Düsseldorf University Hospital), Martin Proescholdt(University Hospital Regensburg), Franziska Friedrich(Goethe University Frankfurt), Ghazaleh Tabatabai(Goethe University Frankfurt), Frederic Mack(University of Bonn), Michael Nießen(University of Bonn), Martin Glas(Essen University Hospital), Martin Uhl(Friedrich-Alexander-Universität Erlangen-Nürnberg), Horst Urbach(University of Freiburg)
Cited by 21
Related Papers
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
|The Lancet Oncology|2006|3.4k
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
|Neurosurgery|2008|1k
Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery
|New England Journal of Medicine|2017|916